An Absolute Bioavailability Study of LY2140023 and LY404039 in Healthy Subjects Using the Intravenous Tracer Method

Trial Profile

An Absolute Bioavailability Study of LY2140023 and LY404039 in Healthy Subjects Using the Intravenous Tracer Method

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2012

At a glance

  • Drugs LY 404039 (Primary) ; LY 404039 (Primary) ; Pomaglumetad methionil (Primary) ; Pomaglumetad methionil (Primary)
  • Indications Schizophrenia
  • Focus Pharmacokinetics
  • Most Recent Events

    • 09 Aug 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.
    • 31 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top